Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Hypertension
How would you approach de-intensifying antihypertensives in frail older adults with SBP <130 mmHg who have nephrotic range proteinuria, given the results of the RETREAT-FRAIL trial?
Benetos A, et al., PMID 40879421
Related Questions
What is your approach for patients who have marked inter-arm blood pressure differences on home and in office measurements?
Do you forgo adrenal imaging in a patient with primary hyperaldosteronism who has decided against surgery?
Do you counsel patients to take antihypertensives at specific times of day to maximize efficacy or minimize side effects?
When would you consider using amiloride over spironolactone for treatment-resistant hypertension (not reaching goal BP on 3 agents, including a diuretic)?
How do you approach checking an aldosterone to renin ratio in an outpatient with hypertension and hypokalemia that is difficult to correct with oral potassium replacement?
What is your approach to managing incidental hypertension without evidence of end-organ damage in hospitalized patients?
Do you recommend patients with hypertensive kidney disease transition from wrist to upper-arm home blood pressure monitoring prior to making dose adjustments to their antihypertensive regimen?
Do you have a preference between an ACEI and ARB when initiating therapy for a patient with diabetic kidney disease, albuminuria, and hypertension?
What is your systolic blood pressure target for patients over 80 with frailty and multiple comorbidities?
Do you recommend transitioning elderly patients from thiazide diuretics to alternative agents when managing hypertension given the increased concern for hyponatremia in this patient population?
